Tratamiento de las complicaciones cardiológicas más frecuentes en pacientes con cáncer
Resumen
Introducción: Con el éxito del tratamiento del cancer , existe un alto riesgo de cardiotoxicidad que se ve reflejado en el notable aumento de casos relacionados a efectos adversos cardiológicos, generando un contexto donde se explica que casi la mitad de la mortalidad por cáncer se deba a enfermedad cardiovascular. Objetivo: Determinar el manejo de las complicaciones cardiológicas en pacientes con cáncer. Metodología: Se realizo una revisión bibliográfica cualitativa de tipo observacional, analítica y descriptiva, sobre tratamiento de las complicaciones cardiológicas en pacientes con cáncer. Resultados: las complicaciones cardiovasculares pueden variar según los medicamentos contra el cáncer, las dosis, el uso en combinación con otros agentes o la radioterapia y los factores de riesgo subyacentes del paciente. Conclusiones: El manejo de las complicaciones cardiológicas debe ser seleccionado con cautela para evitar mayores descompensaciones, donde la prevención de la cardiotoxicidad es un elemento fundamental.
Referencias
Toste JC. Cardio-oncology: Understanding the different mechanisms of cardiovascular toxicity. Rev Port Cardiol. 2022;41(7):587–97.
Kozhukhov SM, Dovganych N V, Smolanka II, Lygyrda OF, Bazyka OY, Lyalkin SA, et al. CARDIOTOXICITY RISK PREDICTION IN BREAST CANCER PATIENTS. Probl radiatsiinoi medytsyny ta radiobiolohii. 2021 Dec;26:498–512.
de Wall C, Bauersachs J, Berliner D. Cardiooncology—dealing with modern drug treatment, long-term complications, and cancer survivorship. Clin Exp Metastasis. 2021;38(4):361–71.
Lax J, Piñeiro D. Consenso de diagnóstico, prevención y tratamiento de la cardiotoxicidad por tratamiento médico del cáncer. Rev Argent Cardiol. 2013;81(6):530–6.
Jeong D, Gladish G, Chitiboi T, Fradley MG, Gage KL, Schiebler ML. MRI in cardio‐oncology: A review of cardiac complications in oncologic care. J Magn Reson Imaging. 2019;50(5):1349–66.
Tocchetti CG, Ameri P, de Boer RA, D’Alessandra Y, Russo M, Sorriento D, et al. Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovasc Res. 2020;116(11):1820–34.
Willems RAL, Winckers K, Biesmans C, de Vos-Geelen J, ten Cate H. Evolving data on cardiovascular complications in cancer. Thromb Res. 2022;213:S87–94.
Boudoulas KD, Triposkiadis F, Gumina R, Addison D, Iliescu C, Boudoulas H. Cardiovascular Disease, Cancer, and Multimorbidity Interactions: Clinical Implications. Cardiology. 2022;147(2):196–206.
Fabiani I, Panichella G, Aimo A, Grigoratos C, Vergaro G, Pugliese NR, et al. Subclinical cardiac damage in cancer patients before chemotherapy. Heart Fail Rev. 2022;27(4):1091–104.
Liang Z, He Y, Hu X. Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology. Int J Mol Sci. 2022;23(18):10617.
Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol. 2019;280:163–75.
Velásquez CA, González M, García-Orjuela MG, Jaramillo N. Enfermedad cardiaca inducida por radioterapia. Rev Colomb Cardiol. 2018;25(1):74–9.
Avellana P, Santos D, Antonietti L, Sampere T, Pocoví A, Domenichini E, et al. An Introduction to Chemotherapy-Related Major Complications a Cardiologist Must Face. Rev Argent Cardiol. 2007;75:55–60.
Gervaso L, Dave H, Khorana AA. Venous and Arterial Thromboembolism in Patients With Cancer. Jacc Cardioncology. 2021;3(2):173–90.
Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, et al. The cancer patient and cardiology. Eur J Heart Fail. 2020;22(12):2290–309.
Yeh ETH, Bickford CL. Cardiovascular Complications of Cancer Therapy. J Am Coll Cardiol. 2009;53(24):2231–47.
Chang H-M, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy. J Am Coll Cardiol. 2017;70(20):2536–51.
Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020 Aug;17(8):474–502.
Cohen JB, Brown NJ, Brown S-A, Dent S, van Dorst DCH, Herrmann SM, et al. Cancer Therapy–Related Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2023;80.
Yang H, Bhoo-Pathy N, Brand JS, Hedayati E, Grassmann F, Zeng E, et al. Risk of heart disease following treatment for breast cancer – results from a population-based cohort study. Elife. 2022;11.
Plana JC. La quimioterapia y el corazón. Rev Española Cardiol. 2011;64(5):409–15.
Zito C, Manganaro R, Ciappina G, Spagnolo CC, Racanelli V, Santarpia M, et al. Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do. Cancers (Basel). 2022;14(21):5403.
Martín García A, Mitroi C, Mazón Ramos P, García Sanz R, Virizuela JA, Arenas M, et al. Stratification and management of cardiovascular risk in cancer patients. Rev Española Cardiol. 2021;74(5):438–48.
Benítez FDM, Noyola AG. Complicaciones Cardiovasculares Postoperatorias en Cirugía Mayor Oncológica. Rev Cuba deCardiología yCirugía Cardiovasc. 2016;22(1):62–9.
Velásquez CA, Berrouet MC, González M, Jaramillo N. Cardiotoxicidad inducida por la quimioterapia desde las bases moleculares hasta la perspectiva clínica. Rev Colomb Cardiol. 2016;23(2):104–11.
Avila MS, Siqueira SRR, Ferreira SMA, Bocchi EA. Prevention and Treatment of Chemotherapy-Induced Cardiotoxicity. Methodist Debakey Cardiovasc J. 2019;15(4):267–73.
Garcia-Garduño TC, Padilla-Gutierrez JR, Cambrón-Mora D, Valle Y. RAAS: A Convergent Player in Ischemic Heart Failure and Cancer. Int J Mol Sci. 2021 Jul;22(13).
Peixoto R, Pereira M de L, Oliveira M. Beta-Blockers and Cancer: Where Are We? Pharmaceuticals (Basel). 2020 May;13(6).
van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J, et al. Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. Circ Res. 2021 Apr;128(7):1040–61.
Das D, Asher A, Ghosh AK. Cancer and Coronary Artery Disease: Common Associations, Diagnosis and Management Challenges. Curr Treat Options Oncol. 2019 May;20(6):46.
Han X-J, Li J-Q, Khannanova Z, Li Y. Optimal management of coronary artery disease in cancer patients. Chronic Dis Transl Med. 2019 Dec;5(4):221–33.
Essa H, Wright DJ, Dobson R, Lip GYH. Chemotherapy-Induced Arrhythmia - Underrecognized and Undertreated. Am J Med. 2021 Oct;134(10):1224-1231.e1.
Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham JW. Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation. Oncology (Williston Park). 2016 Nov;30(11):970–4, 980–1, C3.
Porta‐Sánchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, et al. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. J Am Heart Assoc. 2017 Dec;6(12).
Kim PY, Irizarry-Caro JA, Ramesh T, Iliescu C, Lopez-Mattei JC. How to Diagnose and Manage QT Prolongation in Cancer Patients. JACC CardioOncology. 2021 Mar;3(1):145–9.
Baracaldo-Santamaría D, Llinás-Caballero K, Corso-Ramirez JM, Restrepo CM, Dominguez-Dominguez CA, Fonseca-Mendoza DJ, et al. Genetic and Molecular Aspects of Drug-Induced QT Interval Prolongation. Int J Mol Sci. 2021 Jul;22(15):8090.
Bonaca MP, Olenchock BA, Salem J-E, Wiviott SD, Ederhy S, Cohen A, et al. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation. 2019 Jul;140(2):80–91.
Matzen E, Bartels LE, Løgstrup B, Horskær S, Stilling C, Donskov F. Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases. Cardio-Oncology. 2021 Dec;7(1):27.
Landes U, Iakobishvili Z, Vronsky D, Zusman O, Barsheshet A, Jaffe R, et al. Transcatheter Aortic Valve Replacement in Oncology Patients With Severe Aortic Stenosis. JACC Cardiovasc Interv. 2019 Jan;12(1):78–86.
Ghosh AK, Uk M, Card M, Crake T, Manisty C, Uk M, et al. Pericardial Disease in Cancer Patients. 2018;
Hu J-R, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019 Apr;115(5):854–68.
Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447–58.
Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surg. Eur Heart J. 2015 Nov;36(42):2921–64.
Kirkpatrick EC. Pulmonary Hypertension as a Complication of Pediatric Cancer. Glob Pediatr Heal. 2021;8:2333794X211009094.
Omland T, Heck SL, Gulati G. The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncology. 2022 Mar;4(1):19–37.
Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin [Internet]. 2016 Jul 1 [cited 2023 Feb 2];66(4):309–25. Available from: https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21341
Bojan A, Torok-Vistai T, Parvu A. Assessment and Management of Cardiotoxicity in Hematologic Malignancies. Dis Markers [Internet]. 2021 [cited 2023 Feb 2];2021. Available from: /pmc/articles/PMC7875649/
Kendall SJ, Langley JE, Aghdam M, Crooks BN, Giacomantonio N, Heinze-Milne S, et al. The Impact of Exercise on Cardiotoxicity in Pediatric and Adolescent Cancer Survivors: A Scoping Review. Curr Oncol [Internet]. 2022 Sep 1 [cited 2023 Feb 2];29(9):6350. Available from: /pmc/articles/PMC9497997/
Vejpongsa P, Yeh ETH. Prevention of Anthracycline-Induced Cardiotoxicity: Challenges and Opportunities. J Am Coll Cardiol. 2014 Sep 2;64(9):938–45.
Armenian S, Bhatia S. Predicting and Preventing Anthracycline-Related Cardiotoxicity. Am Soc Clin Oncol Educ B. 2018 May 23;(38):3–12.
Padegimas A, Clasen S, Ky B. Cardioprotective Strategies to Prevent Breast Cancer Therapy-Induced Cardiotoxicity. Trends Cardiovasc Med [Internet]. 2020 Jan 1 [cited 2023 Feb 2];30(1):22. Available from: /pmc/articles/PMC7287268/
Podyacheva E, Toropova Y. Nicotinamide Riboside for the Prevention and Treatment of Doxorubicin Cardiomyopathy. Opportunities and Prospects. Nutrients [Internet]. 2021 Oct 1 [cited 2023 Feb 2];13(10). Available from: /pmc/articles/PMC8538727/
Jurczyk M, Król M, Midro A, Kurnik-łucka M, Poniatowski A, Gil K. Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management. J Clin Med [Internet]. 2021 Oct 1 [cited 2023 Feb 2];10(19):4426. Available from: /pmc/articles/PMC8509845/
Timm KN, Tyler DJ. The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity. Cardiovasc Drugs Ther [Internet]. 2020 Apr 1 [cited 2023 Feb 2];34(2):255. Available from: /pmc/articles/PMC7125062/
Enlaces refback
- No hay ningún enlace refback.
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
